Polymer nanoparticles - A novel strategy for administration of Paclitaxel in cancer chemotherapy

Current Medicinal Chemistry

Volumn 19, Issue 36, 2012, Pages 6207-6213

  Deepa, G ^a   Ashwanikumar, N ^a   Pillai, J J ^a   Kumar, G S V ^a  

^a RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY   (India)

Author keywords

Active; Cancer; Drug; Nanoparticles; Paclitaxel; Passive; PH; Polymer

Indexed keywords

ANTIBODY; APTAMER; FOLIC ACID; NANOPARTICLE; PACLITAXEL; PEPTIDE; POLYMER; TRANSFERRIN;

ANGIOGENESIS; CANCER CHEMOTHERAPY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PENETRATION; DRUG RETENTION; DRUG SOLUBILITY; DRUG STABILITY; DRUG TARGETING; HYDROLYSIS; HYDROPHILICITY; HYDROPHOBICITY; OXIDATION REDUCTION STATE; PARTICLE SIZE; PH; REVIEW; TEMPERATURE;

ANTIBODIES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APTAMERS, NUCLEOTIDE; DRUG CARRIERS; FOLIC ACID; HUMANS; HYDROGEN-ION CONCENTRATION; NANOPARTICLES; NEOPLASMS; PACLITAXEL; PEPTIDES; POLYMERS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 84871273637     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712804485674     Document Type: Review

References (70)

1. Haley, B.; Frenkel, E. Nanoparticles for drug delivery in cancer treatment. J. Urol. Oncol, 2008, 26, 57-64.
2. Links, M.; Brown, R. Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs. Expert. Rev. Mol. Med., 1999, 1-21.
3. Bhalla, K. N.; Microtubule targeted anticancer agents and apoptosis. Oncogene. 2003, 22, 9075-86.
4. Nancy, L.; Elstad; Kirsk, D.; Fowers, Oncogel (ReGel/Paclitaxel) - Clinical Application for a novel paclitaxel delivery system. Adv. Drug Deliv. Rev, 2009, 61, 785-94.
5. K. H. Downing.; E. Nogales. Crystallographic structure of tubulin: implications for dynamic and drug binding, Cell Struct. Funct., 1999, 24, 269-275.
6. J. P. Snyder.; J. H. Nettles.; B. Cornett; K. H. Downing.; E. Nogales. The binding conformation of taxol in beta-tubulin: a model based on electron crystallographic density, Proc. Natl. Acad. Sci. U. S. A. 2001, 98, 5312-5316.
7. M. Abal.; J. M. Andreu. Taxanes: Microtubule and centromere targets, and cell cycle dependent mechanism of action, Curr. Cancer Drug Targets., 2003, 3, 193-203.
8. Kumar, G. N.; Walle, U. K.; Bhalla, K. N.; Walle, T. Binding of taxol to human plasma, albumin and a 1-acid glycoprotein. Res. Comm. Chem. Pathol. Pharm., 1993, 80(3), 337-44.
9. Magadala, P. Multifunctional Polymeric Nanosystems for Tumor-Targeted Delivery. In: V. Torchilin. (Eds.), Multifunctional Pharnaceutical Nanocarriers, E-Publishing: Springer New York, 2008, pp. 33-66.
10. Fessi, H.; Puisieux, F.; Devissaguet, J.; Ammoury, N.; Benita, S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int. J. Pharm., 1989, 55(1), R1-R4.
11. Moghimi, S. M.; Hunter A. C.; Murray, J. C. Long-circulating and target specific nanoparticles: Theory to practice. Pharmacol. Rev., 2001, 53, 283-318.
12. Jain, R. A. The manufacturing techniques of various drug loaded biodegradable poly (lactide-co-glycolide) (PLGA) devices. Biomaterials, 2000, 21, 2475-90.
13. Jain, J. P.; Modi, V.; Domb, A. J.; Kumar, N. Role of polyanhydrides as localized drug carriers. J. Control. Release., 2005, 103, 541-63.
14. Panyam, J.; Labhasetwar, V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Del. Rev, 2003, 55, 329-47.
15. Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotech., 2007, 2, 751-60.
16. Singh, R.; Lillard Jr. J. W. Nanoparticle-based targeted drug delivery. Exp. and Mole. Pathol, 2009, 86, 215-23.
17. Dvorak, H. F.; Nagy, J. A.; Feng, D.; Brown, L. F.; Dvorak, A. M. Vascular permeability factor/vascular endothelial growth factor and the signifcance ofmicrovascular hyper permeability in angiogenesis. Curr. Top. Microbiol. Immunol, 1999, 237, 97-132.
18. Matsumura, Y.; Kimura, M.; Yamamoto, T.; Maeda, H. Involvement of the kinin generating cascade in enhanced vascular permeability in tumor tissue. Jpn. J Cancer Res., 1988, 79, 1327-34.
19. Kaneda, Y.; Tsutsumi, Y.; Yoshioka, Y.; Kamada, H.; Yamamoto, Y.; Kodaira, H.; Tsunoda, S.; Okamoto, T.; Mukai, Y.; Shibata, H.; Nakagawa, S.; Mayumi, T. The use of PVP as a polymeric carrier to improve the plasma half-life of drugs, Biomaterials, 2004, 25(16), 3259-66.
20. Zhu, Z.; Li, Y.; Li, X.; Li, R.; Jia, R.; Liu, B.; Guo, W.; Wu, W.; Jiang, X. Paclitaxel-loaded poly (N-vinylpyrrolidone)-b-poly (e-caprolactone) nanoparticles: Preparation and antitumor activity in vivo. J. Control. Release., 2010, 142, 438-46.
21. Xiao, K.; Luo, J.; Wiley, L.; Fowler; Li, Y.; Joyce, S.; Lee; Xing, L.; Cheng, R. H.; Wang, L.; Lam, K. S. A self assembling nanoparticle for paclitaxel delivery in ovarian cancer. Biomaterials, 2009, 30, 6006-16.
22. Lee, E. S.; Gao, Z.;. Bae, Y H.; Recent progress in tumor pH targeting nanotechnology, J. Control. Release., 2008, 132, 164-70.
23. Engin, K.; Leeper, D. B.; Cater, J. R.; Thistlethwaite, A. J.; Tupchong, L.; McFarlane, Extracellular pH distribution in human tumours. Int. J. Hypertherm., 1995, 11, 211-16.
24. Devalapally, H.; Shenoy, D.; Little, S.; Langer, R.; Amiji, M. Poly (ethylene oxide)-modified poly (beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model. Cancer Chemother. Pharm., 2007, 59(4), 477-84.
25. Chen, W.; Meng, F.; Cheng, R.; Zhong, Z. PH-Sensitive degradable polymersomes for triggered release of anticancer drugs: A comparative study with micelles. J. Control. Release., 2010, 142, 40-46.
26. Li, F.; Wua, H.; Zhang, H.; Li, F.; Gu, C.; Yang, Q. Antitumor drug Paclitaxel-loaded pH-sensitive nanoparticles targeting tumor extracellular pH. Carbohydr. Polym., 2009, 77, 773-78.
27. Griset, A. P.; Walpole, J.; Liu, R.; Gaffey, A.; Colson, Y. L.; Grinstaff, M. W. Expansile Nanoparticles: Synthesis, Characterization, and in Vivo Efficacy of an Acid-Responsive Polymeric Drug Delivery System. J. Am. Chem. Soc., 2009, 131, 2469-71.
28. Meyer, D. E.; Shin, B. C.; Kong, G. A.; Dewhirst, M. W.; Chilkoti, A. Drug targeting using thermally responsive polymers and local hyperthermia. J. Control. Release., 2001, 74, 213-24.
29. Chilkoti, A.; Dreher, M. R.; Meyer, D. E.; Raucher, D. Targeted drug delivery by thermally responsive polymers. Adv. Drug. Deliv. Rev., 2002, 54, 613-30.
30. Schild, H. G. Poly (N-isopropylacrylamide): experiment, theory and application. Prog. Polym. Sci., 1992, 17(2), 163-249.
31. Urry, D. W. Physical chemistry of biological free energy transduction as demonstrated by elastic protein based polymers. J. Phys. Chem. B., 1997, 101, 11007-28.
32. Yoshida, R.; Uchida, K.; Kaneko, Y.; Sakai, K.; Kikuchi, A.; Sakurai, Y.; Okano, T. Comb-type grafted hydrogels with rapid deswelling response to temperature changes. Nature, 1995, 374, 240-42.
33. Bae, K. H.; Choi, S. H.; Park, S. Y.; Lee, Y.; Park, T. G. Thermosensitive pluronic micelles stabilized by shell cross-linking with gold nanoparticles, Langmuir, 2006, 22, 6380-6634.
34. Chun, C. J.; Lee, S. M.; Kim, S. Y.; Yang, H. K.; Song, S. C. Thermosensitive poly (organophosphazene)-paclitaxel conjugate gels for antitumor applications. Biomaterials, 2009, 30, 2349-60.
35. Saito, G.; Swanson, J. A.; Lee, K. D. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv. Drug. Deliv. Rev., 2003, 55(2), 199-215.
36. Ganta, S.; Devalapally, H.; Shahiwala, A.; Amiji, M. A review of stimuliresponsive nanocarriers for drug and gene delivery. J. Control. Release, 2008, 126, 187-204.
37. Niculescu, D. L. Technology evaluation: gemtuzumab ozogamicin, Celltech Group. Curr. Opin. Mol. Ther., 2000, 2, 691-96.
38. Van Vlerken, L. E.; Amiji, M. M. Multi-functional polymeric nanoparticles for tumour targeted drug delivery. Exp. opinion on drug deliv., 2006, 3(2), 205-16.
39. Reis, C. P.; Neufeld, R. J.; Ribeiro, A. J.; Veiga, F. Nanocapsulation I. Methods for preparation of drug loaded polymeric nanoparticles. Nanomed: Nanotech. Biol. and Med., 2006, 2, 8-21.
40. Lee, M.; Lim, S. J.; Kim, C. K. Preparation, characterization and in vitro cytotoxicity of paclitaxel loaded sterically stabilized solid lipid nanoparticles. Biomaterials, 2007, 28, 2137-46.
41. Koo, O. M.; Rubinstein, I.; Onyuskel, H. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomed: Nanotech. Biol. and Med., 2005, 1, 193-212.
42. Nobs, L.; Buchegger, F.; Gurny, R.; Allemann, E. Current methods for attaching targeting ligands to liposomes and nanoparticles. J. Pharm. Sci., 2004, 93, 1980-92.
43. Low, P. S.; Antony, A. C. Folate receptor-targeted drugs for cancer and inflammatory diseases. Adv. Drug. Deliv. Rev., 2004, 56(8), 1055-58.
44. Sudimack, J.; Lee, R. J. Targeted drug delivery via the folate receptor. Adv. Drug. Deliv. Rev., 2000, 41(2), 147-62.
45. Zhao, X. B.; Lee, R. J. Tumour-selective targeted delivery of genes and antisense oligodeoxyribonucleotides via the folate receptor. Adv. Drug Deliv. Rev., 2004, 56(8), 1193-1204.
46. Pan, J.; Feng, S. S. Targeted delivery of paclitaxel using folate-decorated poly (lactide)-vitamin E TPGS nanoparticles. Biomaterials, 2008, 29(17), 2663-72.
47. Park, E. K.; Lee, S. B.; Lee, Y. M. Preparation and characterization of methoxy poly (ethylene glycol)/poly (e-caprolactone) amphiphilic block copolymeric nanospheres for tumor-specific folate-mediated targeting of anticancer drugs. Biomaterials, 2005, 26 1053-61.
48. Li, L.; Wartchow C. A.; Danthi, S. N.; Shen, Z.; Dechene, N.; Pease, J.; Choi, H. S.; Doede, T.; Chu, P.; Ning, S.; Lee, D. Y.; Bednarski, M. D.; S. J. Knox. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. Int. J. Radiat. Oncol. Biol. Phys., 2004, 58(4), 1215-27.
49. Danhier, F.; Vroman, B.; Lecouturier, N.; Crokart, N.; Pourcelle, V.; Freichels, H.; Jérôme, C.; Marchand-Brynaert, J.; Feron, O.; Préat, V. Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with Paclitaxel. J. Control. Release., 2009, 140, 166-73.
50. Singh, M. Transferrin as a targeting ligand for liposomes and anticancer drugs. Curr. Pharm. Des., 1999, 5(6), 443-51.
51. Gatter, K. C.; Brown, G.; Trowbridge, I. S.; Woolston, R. E.; Mason, D. Y. Transferrin receptors in human tissues: their distribution and possible clinical relevance. J. Clin. Pathol., 1983, 36(5), 539-45.
52. Anabousi, S.; Bakowsky, U.; Schneider, M.; Huwer, H.; Lehr, C. M.; Ehrhardt, C. In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer. Eur. J. Pharm. Sci., 2006, 29, 367-74.
53. Sahoo, S. K.; Wenxue, M. A.; Labhasetwar, V. Efficacy of transferrinconjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int. J. Cancer., 2004, 112, 335-40.
54. Xu, Z.; Gu, W.; Huang, J.; Suia, H.; Zhou, Z.; Yang, Y.; Yan, Z.; Li, Y. In vitro and in vivo evaluation of actively targetable nanoparticles for paclitaxel delivery. Int. J. Pharm., 2005, 288, 361-68.
55. Byrne, J. D.; Betancourt, T.; Brannon-Peppas, L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug. Deliv. Rev., 2008, 60, 1615-26.
56. Chapman, A. P. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv. Drug. Deliv. Rev., 2002, 54(4), 531-45.
57. Chapman, A. P.; Antoniw, P.; Spitali, M.; West, S.; Stephens, S.; King, D. J. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat. Biotech., 1999, 17(8), 780-83.
58. Harries, M.; Smith, I. The development and clinical use of trastuzumab (Herceptin). Endocr. Relat. Cancer., 2002, 9(2), 75-85.
59. Kirpotin, D. B.; Drummond, D. C.; Shao, Y.; Shalaby, M. R.; Hong, K.; Nielsen, U. B.; Marks, J. D.; Benz, C. C.; Park, J. W. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res., 2006, 66(13), 6732-40.
60. Cirstoiu-Hapca, A.; Buchegger, F.; Lange, N.; Bossy, L.; Gurny, R.; Delie, F. Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice. J. Control. Release., 2010, 144, 324-31.
61. Chari, R. V. J. Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy. Adv. Drug Deliv. Rev., 1998, 31, 89-104.
62. Guo, K. T.; Paul, A.; Schichor, C.; Ziemer, G.; Wendel, H. P.; CELL-SELEX: Novel Perspectives of Aptamer-Based Therapeutics. Int. J. Mol. Sci., 2008, 9, 668-78.
63. Farokhzad, O. C.; Jon, S.; Khademhosseini, A.; Tran, T. N.; Lavan, D. A.; Langer, R. Nanoparticle aptamer bio conjugates: a new approach for targeting prostate cancer cells. Cancer Res., 2004, 64, 7668-72.
64. Nimjee, S. M.; Rusconi, C. P.; Sullenger, B. A.; Aptamers: an emerging class of therapeutics. Annu. Rev. Med., 2005, 5, 555-83.
65. Farokhzad, O. C.; Karp, J. M.; R. Langer, Nanoparticle-aptamer bio conjugates for cancer targeting, Expert Opin. Drug Deliv., 2006, 3, 311-24.
66. Teng, Y.; Girvan, A. C.; Casson, L. K.; Jr. Pierce, W. M.; Qian, M.; Thomas, S. D.; Bates, P. J.; AS1411 alters the localization of a complex containing protein arginine methyltransferase 5 and nucleolin. Cancer Res., 2007, 67, 10491-500.
67. Cheng, J.; Benjamin, A.; Teply; Sherifi, I.; Sung, J.; Luther G. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials, 2007, 28, 869-76.
68. Regina A.; Demeule M.; Che C.; Lavallee I.; Poirier J.; Gabathuler R.; Beliveau R.; Castaigne J P. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol., 2008, 155(2), 185-197.
69. Donehower, R. Phase I study of DHA-paclitaxel. Clin. Cancer. Res., 2000.6(Suppl.), S4467-S4597.
70. Sabbatini, S. Early findings in a Phase I study of PG-paclitaxel (CT2103) in recurrent ovarian or peritoneal cancer. Clin. Cancer. Res., 7 (Suppl.) 2001, 7, S3653-S3852.